The Heart of Healthcare | A Digital Health Podcast đŁ Digital Health Download: March 2026
Mar 2, 2026
Biotech is back on investors' radars with renewed IPO activity and platform-focused drug discovery. Pharma advertising is surging, raising debates over consumer-targeted drug marketing and legal limits. Hims & Hersâ big acquisition and FDA scrutiny of compounded GLPâ1s make for regulatory drama. A headline-grabbing $1M longevity program sparks questions about evidence and equity.
AI Snips
Chapters
Books
Transcript
Episode notes
Pharma Ads Drive Demand More Than Outcomes
- Direct-to-consumer pharma advertising changes patient and physician behavior, increasing prescriptions and utilization.
- Hallie cites a 2023 JAMA finding that ~75% of heavily advertised drugs offered no meaningful benefit over older alternatives, raising questions about value.
First Amendment Shapes Any Pharma Ad Restrictions
- Legal limits on pharma ads face First Amendment commercial speech tests focusing on government interest and tailoring.
- Michael explains restrictions could pass if public health and drug safety demonstrate substantial government interest and appropriate tailoring.
Hims & Hers Betting Big On Global Telehealth
- Hims & Hers is pursuing global scale via acquisitions like Eucalyptus for $1.15B and Zava last year.
- Michael notes this strategy is unusual because care delivery is typically local due to licensing, reimbursement, and clinical standards.
